Claudia Gravekamp

Papers

Total Citations

792

H-Index

About

Claudia Gravekamp is a pioneering figure in cancer immunotherapy, best known for her groundbreaking work in engineering bacteria to target and treat tumors. Her research focuses on the intersection of microbiology and oncology, particularly the use of attenuated *Listeria monocytogenes* as a vehicle for delivering therapeutic agents directly to cancer cells. Gravekamp’s major contribution lies in demonstrating how these tumor-targeting bacteria can be harnessed to stimulate potent anti-tumor immune responses, effectively turning the body’s own defenses against malignancies. Her landmark 2018 paper, "Tumour-targeting bacteria engineered to fight cancer," has garnered over 790 citations, underscoring its profound impact on the field. This work not only advanced the concept of bacterial-based cancer therapy but also paved the way for clinical trials exploring its efficacy. Gravekamp’s innovative approach has been recognized as a transformative strategy in immunotherapy, offering new hope for treating aggressive cancers that resist conventional treatments. Her achievements highlight the power of interdisciplinary research, merging microbiology and immunology to create novel, targeted cancer therapies.